DE68928432D1 - Legionellosis-impfstoffe und verfahren zur herstellung - Google Patents

Legionellosis-impfstoffe und verfahren zur herstellung

Info

Publication number
DE68928432D1
DE68928432D1 DE68928432T DE68928432T DE68928432D1 DE 68928432 D1 DE68928432 D1 DE 68928432D1 DE 68928432 T DE68928432 T DE 68928432T DE 68928432 T DE68928432 T DE 68928432T DE 68928432 D1 DE68928432 D1 DE 68928432D1
Authority
DE
Germany
Prior art keywords
vaccines
legionellosis
vaccine
pathogen
production method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68928432T
Other languages
English (en)
Other versions
DE68928432T2 (de
Inventor
Marcus Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE68928432D1 publication Critical patent/DE68928432D1/de
Application granted granted Critical
Publication of DE68928432T2 publication Critical patent/DE68928432T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE68928432T 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur herstellung Expired - Lifetime DE68928432T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07232664 US5108745B1 (en) 1988-08-16 1988-08-16 Tuberculosis and legionellosis vaccines and methods for their production
PCT/US1989/003486 WO1990001944A1 (en) 1988-08-16 1989-08-15 Legionellosis vaccines and methods for their production

Publications (2)

Publication Number Publication Date
DE68928432D1 true DE68928432D1 (de) 1997-12-11
DE68928432T2 DE68928432T2 (de) 1998-03-05

Family

ID=22874048

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68928432T Expired - Lifetime DE68928432T2 (de) 1988-08-16 1989-08-15 Legionellosis-impfstoffe und verfahren zur herstellung
DE68929318T Expired - Lifetime DE68929318T2 (de) 1988-08-16 1989-08-15 Legionellosis-Impfstoffe und Verfahren zur deren Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68929318T Expired - Lifetime DE68929318T2 (de) 1988-08-16 1989-08-15 Legionellosis-Impfstoffe und Verfahren zur deren Herstellung

Country Status (7)

Country Link
US (1) US5108745B1 (de)
EP (2) EP0432203B1 (de)
JP (1) JP2841094B2 (de)
AT (2) ATE159857T1 (de)
CA (1) CA1337333C (de)
DE (2) DE68928432T2 (de)
WO (1) WO1990001944A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509151B1 (en) * 1993-09-02 2003-01-21 Cornell Research Foundation, Inc. DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof
US7300660B2 (en) * 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6818223B2 (en) * 1993-11-23 2004-11-16 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
EP0771322B9 (de) 1993-11-23 2009-08-12 The Regents Of The University Of California Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6072048A (en) * 1997-03-10 2000-06-06 Cornell Research Foundation, Inc. DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof
AU7166798A (en) 1997-05-06 1998-11-27 Cornell Research Foundation Inc. Dna molecule conferring on (mycobacterium tuberculosis) resistance against antimicrobial reactive oxygen and nitrogen intermediates
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000066143A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0012258D0 (en) 2000-05-19 2000-07-12 Fujitsu Ltd Transmission rate changes in communications networks
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US20040157802A1 (en) * 2002-11-15 2004-08-12 Marcus Horwitz Anti-microbial agents derived from methionine sulfoximine analogues
US7901932B2 (en) * 2005-03-17 2011-03-08 Phigenics, Llc Methods and compositions for rapidly detecting and quantifying viable Legionella
ATE536551T1 (de) * 2005-03-17 2011-12-15 Phigenics Llc Methode zum schnellen nachweisen und quantifizieren lebensfähiger legionellen
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514509A (en) * 1981-09-21 1985-04-30 Indiana University Foundation Method for the diagnosis of Legionnaires' disease
GB8301600D0 (en) * 1983-01-21 1983-02-23 Btp Cocker Chem Ltd Control of legionella pneumophila in water systems
FR2541304A1 (fr) * 1983-02-21 1984-08-24 Centre Nat Rech Scient Anticorps monoclonaux anti-legionella, procede d'obtention et application au diagnostic de pneumonies
US4722891A (en) * 1984-06-20 1988-02-02 Board Of Regents, The University Of Texas System Methods and compositions for detection of Legionnaires' disease

Also Published As

Publication number Publication date
DE68929318D1 (de) 2001-09-06
ATE159857T1 (de) 1997-11-15
EP0753310A1 (de) 1997-01-15
US5108745A (en) 1992-04-28
EP0753310B1 (de) 2001-08-01
WO1990001944A1 (en) 1990-03-08
US5108745B1 (en) 1998-06-30
CA1337333C (en) 1995-10-17
DE68929318T2 (de) 2002-05-08
JP2841094B2 (ja) 1998-12-24
ATE203677T1 (de) 2001-08-15
JPH04501107A (ja) 1992-02-27
EP0432203A1 (de) 1991-06-19
EP0432203B1 (de) 1997-11-05
EP0432203A4 (en) 1991-11-06
DE68928432T2 (de) 1998-03-05

Similar Documents

Publication Publication Date Title
DE68928432D1 (de) Legionellosis-impfstoffe und verfahren zur herstellung
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
ES2092306T3 (es) Adyuvante para vacunas.
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
FI113969B (fi) Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
EP0855918A4 (de) Interleukin-15 aus hühnern und seine verwendungen
ES543026A0 (es) Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina.
DE3806565A1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
IT1113070B (it) Vaccino costituito da virus vivente per la vaccinazione contro la pseudipeste del pollame ed affini e metodo per la sua preparazione
FI875015A (fi) Vaccin mot juverinflammation.
ATE149569T1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
ATE273022T1 (de) Verfahren zur verstärkung zellularer immunantworten
EP0023731A3 (de) Verfahren zur Herstellung polyvalenter Virus-Impfstoffe in einem Einzelzellsystem, solche polyvalenten Impfstoffe und ihre Verwendung
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
CA2382336A1 (en) Vaccines from infectious agents
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
AT410172B (de) Verfahren zur herstellung einer vakzineformulierung
DE69403197D1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind
TH809EX (th) โปรโตโซลแอนติเจล (กรรมวิธี)
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
TH3933EX (th) วัคซีนที่มีขอบเขตของการออกฤทธิ์กว้างที่ใช้ต่อต้านโรคโกโนเรีย

Legal Events

Date Code Title Description
8364 No opposition during term of opposition